# Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

> **NCT04323748** · PHASE1 · RECRUITING · sponsor: **New York Medical College** · enrollment: 20 (estimated)

## Conditions studied

- Immune Thrombocytopenic Purpura

## Interventions

- **DRUG:** rituxan

## Key facts

- **NCT ID:** NCT04323748
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-24
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04323748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04323748, "Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04323748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*